The CD40-CD40 ligand (CD40L) pathway is a backbone of communication between cells of the immune system. It makes it possible to generate a proinflammatory signal and thus participates in the pathogenesis of dysimmune diseases, transplant rejection and atherosclerosis. Because of this therapeutic target of choice, several generations of anti-CD40L monoclonal antibodies have emerged since the 1990s. The first generation of antibodies was responsible for thromboembolic toxicity for which the mechanisms are starting to be defined. New generations of antibodies were designed to overcome this toxicity and are still being developed in lupus, rheumatoid arthritis, Sjogren's syndrome or immunologic thrombocytopenia. In addition to these targeted therapies, there are data suggesting the impact of several drugs among molecules used in cardiology and clinical immunology on the level of CD40L. The objective of this review is to recall the clinical issues related to the CD40-CD40L axis and to present current or future treatments that block CD40L which would allow clinicians to diversify their options for managing dysimmune diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.revmed.2021.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Small-molecule inhibitors of the CD40-CD40L costimulatory interaction are effective in pancreatic islet transplantation and prevention of type 1 diabetes models.
Front Immunol
November 2024
Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL, United States.
Article Synopsis
- - The research focuses on developing small-molecule inhibitors (SMIs) targeting the CD40-CD40L interaction to improve islet transplantation outcomes and prevent type 1 diabetes (T1D) in mice.
- - Promising SMIs DRI-C21041 and DRI-C21095 demonstrated the ability to prolong islet allograft survival and functionality while reducing T1D incidence in NOD mice during trials.
- - These findings suggest that CD40L-targeting SMIs could provide a safer and more effective alternative to traditional antibody treatments, offering better control and ease of administration for transplant recipients and autoimmune disease prevention.
Effect of Diminazene Aceturate, an ACE2 activator, on platelet CD40L signaling induced glial activation in rat model of hypertension.
Int Immunopharmacol
September 2024
Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Hypertension causes platelet activation and adhesion in the brain resulting in glial activation and neuroinflammation. Further, activation of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor (ACE2/Ang (1-7)/MasR) axis of central Renin-Angiotensin System (RAS), is known to reduce glial activation and neuroinflammation, thereby exhibiting anti-hypertensive and anti-neuroinflammatory properties. Therefore, in the present study, the role of ACE2/Ang (1-7)/MasR axis was studied on platelet-induced glial activation and neuroinflammation using Diminazene Aceturate (DIZE), an ACE2 activator, in astrocytes and microglial cells as well as in rat model of hypertension.
View Article and Find Full Text PDFDevelopment of an immunoassay for quantification of soluble human CD40L (CD154) in plasma and serum samples.
J Immunol Methods
August 2024
Department of Biomedicine, Aarhus University, Denmark. Electronic address:
When the membrane protein CD40 ligand (CD40L) on activated T cells binds the receptor CD40 on B-cells, it provides a co-stimulatory signal for B cell activation. Dysregulation of the CD40L:CD40 axis is associated with inflammatory and autoimmune diseases. The presence of soluble CD40L (sCD40L) in plasma is implicated in several diseases, from cardiovascular and autoimmune diseases to different types of cancer, and sCD40L has been suggested as a valuable marker of disease.
View Article and Find Full Text PDFRole of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in diabetes and hypertension-insights from animal and human studies.
Basic Res Cardiol
August 2024
Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Article Synopsis
- CD40L-CD40-TRAF signaling is implicated in the progression of atherosclerosis and the pathogenesis of coronary heart disease (CHD), especially in individuals with comorbid conditions like hyperlipidemia, diabetes, and hypertension.
- In mouse models with diabetes and hypertension, treatment with a TRAF6 inhibitor showed promising results by normalizing oxidative stress and inflammation markers, suggesting that this signaling pathway could serve as a therapeutic target.
- Analysis of plasma and vascular materials from CHD patients revealed a correlation between elevated inflammatory markers and comorbidities, indicating that addressing these inflammatory pathways could help reduce cardiovascular events in affected individuals.
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Hemasphere
April 2023
Department of Medicine III - Hematology/Oncology, University Hospital, LMU Munich, Germany.
Early fever after chimeric antigen receptor T-cell (CAR-T) therapy can reflect both an infection or cytokine release syndrome (CRS). Identifying early infections in the setting of CRS and neutropenia represents an unresolved clinical challenge. In this retrospective observational analysis, early fever events (day 0-30) were characterized as infection versus CRS in 62 patients treated with standard-of-care CD19.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!